Efficacy and safety of NNC6019-0001 at two dose levels in participants with transthyretin amyloid cardiomyopathy (ATTR CM).
Researchers are conducting a study to see how safe and effective a new medicine called coramitug is for people living with a heart condition called transthyretin amyloid cardiomyopathy (ATTR CM). This condition affects the heart's ability to pump blood properly. The study will involve giving some participants coramitug and others an inactive substance (placebo) to compare the effects. Doctors will measure how well participants can walk in six minutes and check certain blood markers related to heart health over a 52-week period. They will also look at how the heart's structure changes, overall quality of life, and any side effects. This research aims to find better ways to manage ATTR CM.
At a glance
What is this study about?
This study is exploring a new medicine for a heart condition called transthyretin amyloid cardiomyopathy, often shortened to ATTR CM. In this condition, abnormal proteins build up in the heart, making it stiff and harder for it to pump blood effectively. This can lead to symptoms like shortness of breath and tiredness.
The main goal of this particular study, which is in an early phase (Phase II), is to find out if the new medicine, coramitug, is both safe and helpful. Researchers will give some people with ATTR CM the new medicine, while others will receive a 'placebo' – an inactive substance that looks just like the real medicine. This allows them to see if any improvements are genuinely due to coramitug or if they might have happened anyway.
Over roughly a year, the study will carefully track how well participants can walk in six minutes, as a way to measure their physical ability. They'll also check important blood tests that give clues about heart health. Beyond these main checks, the study will also look at other aspects like changes in the heart's structure, how participants feel in their daily lives, and any side effects that might occur. The information gathered will help doctors understand if coramitug could be a useful new treatment option for ATTR CM.
Key takeaways
- This study is testing a new heart medicine called coramitug.
- It's for people with a heart condition called ATTR CM.
- The study compares coramitug to a dummy medicine (placebo).
- It will check heart health and how well people can walk over roughly a year.
- Participation involves regular clinic visits for about 15 months.
- You can stop participating at any time if you wish.
Who may be eligible?
To join this study, you must have already been diagnosed with transthyretin amyloid cardiomyopathy (ATTR CM).
Participants need to be at least 18 years old. There's no upper age limit, meaning people of all adult ages can be considered. Both men and women are welcome to take part in this research.
It's important to remember that these are just the basic requirements. A doctor involved in the study will need to check your full medical history and other health details to make sure the study is a safe and suitable option for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with transthyretin amyloid cardiomyopathy (ATTR CM)?
- Are you able to attend regular clinic appointments for over a year?
- Are you willing to potentially receive an inactive 'placebo' treatment?
What does participation involve?
Taking part in this study would involve regular visits to a clinic over about 15 months (64 weeks). During these visits, you would receive either the study medicine (coramitug) or a placebo, which looks identical to the medicine but contains no active drug. You wouldn't know which one you're receiving.
Throughout the study, doctors and nurses will carry out various health checks. These will include a '6-minute walk test' to see how far you can walk in that time, blood tests to check heart health, and probably some heart scans. You might also fill out questionnaires about your quality of life and general well-being. Regular checks for any side effects will also be part of your appointments. The total duration of active treatment and follow-up for safety is 64 weeks.
Potential risks and benefits
Locations (7)
- —UnverifiedPortugal
- —UnverifiedNetherlands
- —UnverifiedGermany
- —UnverifiedSpain
- —UnverifiedCzechia
- —UnverifiedItaly
- —UnverifiedFrance
Common questions
What is transthyretin amyloid cardiomyopathy (ATTR CM)?
It's a heart condition where abnormal proteins build up in the heart, making it stiff and less able to pump blood efficiently.
What does a 'placebo' mean?
A placebo is a 'dummy' treatment that looks like the real medicine but has no active ingredients. It helps researchers see if the real medicine actually works.
How long will I be in the study?
The study involves regular visits over about 15 months (64 weeks).
Will I know if I'm getting the active medicine?
No, during the study, you won't know if you're receiving the active medicine or the placebo. This helps ensure the results are fair.
Can I leave the study if I change my mind?
Yes, you are free to leave the study at any time, for any reason, and it won't affect your ongoing medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.